Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Neuroprotective Effect of Curcumin on the Nigrostriatal Pathway in a 6-Hydroxydopmine-Induced Rat Model of Parkinson's Disease is Mediated by α7-Nicotinic Receptors.

Tytuł:
Neuroprotective Effect of Curcumin on the Nigrostriatal Pathway in a 6-Hydroxydopmine-Induced Rat Model of Parkinson's Disease is Mediated by α7-Nicotinic Receptors.
Autorzy:
El Nebrisi E; Department of Pharmacology, Dubai Medical College, Dubai Medical University, Dubai 20170, UAE.; Department of Anatomy, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain PO BOX 17666, UAE.
Javed H; Department of Anatomy, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain PO BOX 17666, UAE.
Ojha SK; Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain PO BOX 17666, UAE.
Oz M; Department of Pharmacology and Therapeutics, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain PO BOX 17666, UAE.; Department of Pharmacology and Therapeutics, College of Pharmacy, Kuwait University, Kuwait 24923, Kuwait.
Shehab S; Department of Anatomy, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain PO BOX 17666, UAE.
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2020 Oct 03; Vol. 21 (19). Date of Electronic Publication: 2020 Oct 03.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:
Curcumin/*pharmacology
Parkinson Disease/*drug therapy
Parkinson Disease, Secondary/*drug therapy
alpha7 Nicotinic Acetylcholine Receptor/*genetics
Animals ; Corpus Striatum/drug effects ; Corpus Striatum/metabolism ; Corpus Striatum/pathology ; Disease Models, Animal ; Dopamine/metabolism ; Dopaminergic Neurons/drug effects ; Dopaminergic Neurons/pathology ; Humans ; Oxidopamine/toxicity ; Parkinson Disease/genetics ; Parkinson Disease/pathology ; Parkinson Disease, Secondary/chemically induced ; Parkinson Disease, Secondary/genetics ; Parkinson Disease, Secondary/pathology ; Rats ; Substantia Nigra/drug effects ; Substantia Nigra/pathology ; alpha7 Nicotinic Acetylcholine Receptor/administration & dosage
References:
Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):535-40. (PMID: 12050094)
Acta Pharm Sin B. 2017 Nov;7(6):611-622. (PMID: 29159020)
Pathol Res Pract. 2014 Jun;210(6):357-62. (PMID: 24642369)
J Neurochem. 2006 Sep;98(6):1866-75. (PMID: 16882311)
Mol Ther. 2016 Apr;24(4):746-58. (PMID: 26700614)
Free Radic Res. 2005 Oct;39(10):1119-25. (PMID: 16298737)
Transl Neurodegener. 2017 Oct 25;6:28. (PMID: 29090092)
Prog Brain Res. 2000;125:27-47. (PMID: 11098652)
Cardiovasc Psychiatry Neurol. 2012;2012:942981. (PMID: 22928089)
J Neurol. 2000 Apr;247 Suppl 2:II3-10. (PMID: 10991663)
Lancet Neurol. 2006 Jun;5(6):525-35. (PMID: 16713924)
Brain Res. 2011 Jan 12;1368:254-63. (PMID: 20951685)
Mov Disord. 2011 May;26(6):1056-71. (PMID: 21626551)
Trends Neurosci. 2004 Aug;27(8):468-74. (PMID: 15271494)
Brain Res. 2004 Aug 6;1016(2):170-81. (PMID: 15246853)
Neurosci Lett. 1992 Oct 26;146(1):87-90. (PMID: 1475054)
Nat Neurosci. 2001 Dec;4(12):1224-9. (PMID: 11713470)
Pharmacol Ther. 2013 Jan;137(1):22-54. (PMID: 22925690)
Brain Res. 2002 Nov 29;956(2):358-66. (PMID: 12445706)
Neurosci Bull. 2012 Jun;28(3):253-8. (PMID: 22622825)
Food Chem Toxicol. 2011 Aug;49(8):1834-42. (PMID: 21571027)
Trends Neurosci. 1999 Feb;22(2):51-61. (PMID: 10092043)
Inflammopharmacology. 2008 Apr;16(2):96-9. (PMID: 18408903)
Exp Neurol. 2015 Jan;263:277-84. (PMID: 25261754)
Physiol Rev. 2009 Jan;89(1):73-120. (PMID: 19126755)
Cell Physiol Biochem. 2017;43(6):2226-2241. (PMID: 29069652)
Neuropathol Appl Neurobiol. 2016 Feb;42(1):33-50. (PMID: 26662475)
Brain Res. 1981 Nov 30;225(2):373-85. (PMID: 6118197)
Anesth Analg. 2015 Nov;121(5):1369-77. (PMID: 26280585)
BMC Complement Altern Med. 2017 Aug 17;17(1):412. (PMID: 28818104)
Exp Neurol. 2012 May;235(1):306-15. (PMID: 22394547)
Eur J Neurosci. 2003 Apr;17(7):1329-37. (PMID: 12713636)
Brain Res. 1992 May 22;581(1):67-80. (PMID: 1354008)
Behav Brain Res. 2006 Apr 25;169(1):1-9. (PMID: 16413939)
Exp Neurol. 1998 Aug;152(2):259-77. (PMID: 9710526)
Neurosci Lett. 2011 Feb 11;489(3):192-6. (PMID: 21167259)
Brain Res. 1991 Jul 19;554(1-2):46-55. (PMID: 1933318)
Prog Neurobiol. 1996 Oct;50(2-3):275-331. (PMID: 8971983)
CNS Drug Rev. 2004 Summer;10(2):147-66. (PMID: 15179444)
Front Neurosci. 2016 Aug 02;10:321. (PMID: 27531971)
Neuroscientist. 2016 Jun;22(3):266-77. (PMID: 25761946)
Nat Med. 2001 Oct;7(10):1144-50. (PMID: 11590439)
Mol Pharmacol. 2016 Sep;90(3):288-99. (PMID: 27190210)
J Neurobiol. 2002 Dec;53(4):590-605. (PMID: 12436423)
Neurochem Int. 2018 Mar;114:80-84. (PMID: 29341902)
BMC Complement Altern Med. 2006 Mar 17;6:10. (PMID: 16545122)
Curr Drug Targets CNS Neurol Disord. 2002 Aug;1(4):399-411. (PMID: 12769612)
Mov Disord. 2012 Jul;27(8):947-57. (PMID: 22693036)
J Neurosci. 1987 Dec;7(12):3915-34. (PMID: 2891799)
J Neurosci Methods. 1995 Sep-Oct;61(1-2):113-8. (PMID: 8618408)
Eur Neuropsychopharmacol. 2016 Sep;26(9):1401-1411. (PMID: 27474687)
Neuroscience. 2014 Jun 13;270:212-25. (PMID: 24755486)
Exp Brain Res. 2006 Aug;173(2):274-81. (PMID: 16676172)
Front Psychiatry. 2013 Apr 30;4:29. (PMID: 23641218)
Biochem Pharmacol. 2013 Oct 15;86(8):1208-14. (PMID: 23948066)
Neuropharmacology. 2015 Sep;96(Pt B):302-11. (PMID: 25460185)
Nat Rev Neurol. 2013 Jan;9(1):13-24. (PMID: 23183883)
J Pharmacol Exp Ther. 2018 Apr;365(1):190-200. (PMID: 29339457)
Neurochem Int. 2018 Mar;114:33-41. (PMID: 29305920)
Cold Spring Harb Perspect Med. 2012 Jan;2(1):a008888. (PMID: 22315721)
Mov Disord. 2011 May;26(6):1049-55. (PMID: 21626550)
Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S123-5. (PMID: 22166408)
Auton Neurosci. 2014 May;182:65-9. (PMID: 24411268)
Inflammopharmacology. 2017 Feb;25(1):69-79. (PMID: 27853890)
J Autism Dev Disord. 2016 Dec;46(12):3812-3817. (PMID: 27565651)
Pharmacol Ther. 2017 Nov;179:1-16. (PMID: 28529069)
Eur J Pharmacol. 2000 Mar 30;393(1-3):3-10. (PMID: 10770992)
Front Biosci. 2008 Jan 01;13:492-504. (PMID: 17981563)
Exp Neurol. 2014 Jul;257:25-38. (PMID: 24747357)
Neuron. 1990 Dec;5(6):847-56. (PMID: 1702646)
FEBS Lett. 1996 Nov 25;398(1):91-6. (PMID: 8946959)
Neuron. 2006 Jun 15;50(6):911-21. (PMID: 16772172)
Neurobiol Dis. 2011 Sep;43(3):725-35. (PMID: 21689751)
J Microsc. 1987 Sep;147(Pt 3):229-63. (PMID: 3430576)
Neuropharmacology. 2013 Feb;65:156-64. (PMID: 23079470)
Br J Pharmacol. 2012 Sep;167(2):421-35. (PMID: 22536953)
Neuropharmacology. 2013 Oct;73:337-47. (PMID: 23770260)
Neuroscience. 2017 Jan 6;340:308-318. (PMID: 27826109)
Neurosci Res. 2008 Apr;60(4):355-63. (PMID: 18242749)
Pathol Res Pract. 2016 Apr;212(4):247-51. (PMID: 26922613)
Grant Information:
31M290 United Arab Emirates University
Contributed Indexing:
Keywords: 6-OHDA; Parkinson’s disease; curcumin; neuroprotection; α7-nAChR
Substance Nomenclature:
0 (alpha7 Nicotinic Acetylcholine Receptor)
8HW4YBZ748 (Oxidopamine)
IT942ZTH98 (Curcumin)
VTD58H1Z2X (Dopamine)
Entry Date(s):
Date Created: 20201007 Date Completed: 20210223 Latest Revision: 20210223
Update Code:
20240105
PubMed Central ID:
PMC7583812
DOI:
10.3390/ijms21197329
PMID:
33023066
Czasopismo naukowe
Parkinson's disease (PD) is a common neurodegenerative disorder, characterized by selective degeneration of dopaminergic nigrostriatal neurons. Most of the existing pharmacological approaches in PD consider replenishing striatal dopamine. It has been reported that activation of the cholinergic system has neuroprotective effects on dopaminergic neurons, and human α7-nicotinic acetylcholine receptor (α7-nAChR) stimulation may offer a potential therapeutic approach in PD. Our recent in-vitro studies demonstrated that curcumin causes significant potentiation of the function of α7-nAChRs expressed in Xenopus oocytes. In this study, we conducted in vivo experiments to assess the role of the α7-nAChR on the protective effects of curcumin in an animal model of PD. Intra-striatal injection of 6-hydroxydopmine (6-OHDA) was used to induce Parkinsonism in rats. Our results demonstrated that intragastric curcumin treatment (200 mg/kg) significantly improved the abnormal motor behavior and offered neuroprotection against the reduction of dopaminergic neurons, as determined by tyrosine hydroxylase (TH) immunoreactivity in the substantia nigra and caudoputamen. The intraperitoneal administration of the α7-nAChR-selective antagonist methyllycaconitine (1 µg/kg) reversed the neuroprotective effects of curcumin in terms of both animal behavior and TH immunoreactivity. In conclusion, this study demonstrates that curcumin has a neuroprotective effect in a 6-hydroxydopmine (6-OHDA) rat model of PD via an α7-nAChR-mediated mechanism.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies